PTC Therapeutics Executive Compensation
PTC Therapeutics is a publicly traded company in the Healthcare sector.
Named Executive Officers — FY2025
Compensation Analysis
Computed directly from SEC-sourced figures tracked on this page — not a general description.
PTC Therapeutics's available SEC proxy filings disclose compensation for a single named executive officer: Matthew B. Klein (Executive Officer).
Matthew B. Klein's total compensation rose 214% year-over-year, from $7.4M in FY2024 to $23.3M in FY2025.
Cash compensation (salary plus bonus) made up 4% of PTC Therapeutics's FY2025 tracked executive pay, with stock awards accounting for 0%.
Among 78 other Healthcare companies in this dataset, PTC Therapeutics's combined tracked executive pay of $23.3M ranks in the 77th percentile (industry median: $12.5M). Its highest-paid executive, Matthew B. Klein, ranks in the 95th percentile for top-executive pay in the sector (industry median: $6.0M).
Compensation figures on this page for PTC Therapeutics come directly from its SEC DEF 14A proxy statement(s), filed with the SEC via EDGAR — not from crowdsourced or self-reported salary data.